$0.048
+0.023 (+48.61%)收盤時
IOBT 資訊
IOBT 事件
IO Biotech Retains Raymond James as Financial Advisor
IO Biotech announced that it has retained Raymond James & Associates to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives. The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company's workforce, to reduce operating expenses while the company explores strategic alternatives.
Major Averages Close Broadly Higher as Investors Brace for Earnings Reports
The major averages closed broadly higher as traders brace for another week of corporate earnings reports, including from big names Microsoft, Apple, and Tesla, as well as the latest Federal Reserve interest rate decision slated for later this week.Investors are also monitoring even more tariff news, as President Trump over the weekend threatened 100% tariffs on all Canadian goods and products if the country reaches a trade agreement with China. However, Prime Minister Mark Carney said that Canada has "no intention" of pursuing such a trade deal. Additionally, rising tensions in Minnesota remain in focus following another fatal shooting of a U.S. citizen by an ICE officer over the weekend. Amid all the news coming out of the state, a group of more than 60 CEOs of Minnesota-based companies called for an "immediate de-escalation of tensions."Looking to commodities, gold continues to soar to record highs, surpassing the $5,000 mark for the first time.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:A group of more than 60 CEOs of Minnesota-based companies, including 3M, Target, UnitedHealth, and Best Buy, called for anin the stateNvidiaisin CoreWeaveUSA Rare Earthentered into a non-binding Letter of Intent with the U.S. government forMerckis no longer in talks to acquire Revolution Medicines,IonQSkyWater Technologyfor $35 per share in cash and stock2. WALL STREET CALLS:Meta Platformsto Buy at Rothschild & Co RedburnCiscoto Outperform at Evercore ISIBTIGof Fannie Maeand Freddie Macwith Buy ratings and $20 price targetsVaronisto Equal Weight from Overweight at Morgan StanleyPiperIO Biotech, sees no assurance strategic alternatives process will pan out favorably3. AROUND THE WEB:Oil majors that operate the Karachaganak field in Kazakhstan, including Eniand Shelllost an international arbitration case, leaving them liable to pay as much as $4B, Bloomberg reportsNikeis looking into a potential data breach, Reuters saysA foreign investment fund is in advanced talks to acquire Israeli medical aesthetics firm InModefor about $1.1B, or a 25% premium to its $882M valuation, which would result in the company being delisted, Calcalist reportsGooglehas acquired Common Sense Machines, which offers AI models that create 3D assets from 2D images, The Information saysMeta'sdecision to deprioritize VR in favor of AI and internet-connected glasses has chilled the VR industry, leading to concerns about its future, CNBC reports4. MOVERS:Land's Endhigher after announcing an agreement with WHP Global toTronoxincreases after providing Q4 guidance and announcing theSareptagains after reporting topline three-yearSatellogicfalls after pricing 7.4M shares at $4.73 inBlackRock TCP Capitallower after5. EARNINGS/GUIDANCESteel Dynamics, with EPS beating consensusBank of Hawaii, with CEO Peter Ho commenting, "Bank of Hawai'i completed 2025 with strong financial performance"Velocity Financialprovidedand FY25Trade Deskreaffirmed itsLakeland Financial, with CEO David Findlay commenting, "The Lake City Bank team produced a very strong fourth quarter with exceptional performance metrics"INDEXES:The Dow rose 313.69, or 0.64%, to 49,412.40, the Nasdaq gained 100.11, or 0.43%, to 23,601.36, and the S&P 500 advanced 34.62, or 0.50%, to 6,950.23.
Major Averages Rebound, Nasdaq Up 0.67%
The major averages were broadly higher near noon following last week's losses. Traders are bracing for another week of corporate earnings reports, including from big names Microsoft, Apple, and Tesla, as well as the latest Federal Reserve interest rate decision slated for later this week.Meanwhile, investors are also monitoring even more tariff news, as President Trump over the weekend threatened 100% tariffs on all Canadian goods and products if the country reaches a trade agreement with China, though Prime Minister Mark Carney said that Canada has "no intention" of pursuing such a trade deal. Additionally, rising tensions in Minnesota remain in focus following another fatal shooting of a U.S. citizen by an ICE officer over the weekend. Amid all the news coming out of the state, a group of more than 60 CEOs of Minnesota-based companies called for an "immediate deescalation of tensions."Looking to commodities, gold continues to soar to record highs, surpassing the $5,000 mark for the first time. Oil prices were lower near noon, meanwhile, as traders await more news coming out of Venezuela.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:A group of more than 60 CEOs of Minnesota-based companies, including 3M, Target, UnitedHealth, and Best Buy, called for anin the stateNvidiaisin CoreWeaveUSA Rare Earthentered into a non-binding Letter of Intent with the U.S. government forMerckis no longer in talks to acquire Revolution Medicines,IonQSkyWater Technologyfor $35 per share in cash and stock2. WALL STREET CALLS:Meta Platformsto Buy at Rothschild & Co RedburnCiscoto Outperform at Evercore ISIBTIGof Fannie Maeand Freddie Macwith Buy ratings and $20 price targetsVaronisto Equal Weight from Overweight at Morgan StanleyPiperIO Biotech, sees no assurance strategic alternatives process will pan out favorably3. AROUND THE WEB:A foreign investment fund is in advanced talks to acquire Israeli medical aesthetics firm InModefor about $1.1B, or a 25% premium to its $882M valuation, which would result in the company being delisted, Calcalist reportsGooglehas acquired Common Sense Machines, which offers AI models that create 3D assets from 2D images, The Information saysMeta'sdecision to deprioritize VR in favor of AI and internet-connected glasses has chilled the VR industry, leading to concerns about its future, CNBC reportsSome LVMHshareholders are looking for clarity on how and to whom CEO Bernard Arnault plans to hand over leadership of the company, Reuters saysSnowcap Research is short Patria Investmentsas its investigation suggests the company may be overstating performance and concealing losses within its flagship private equity and infrastructure funds4. MOVERS:Land's Endhigher after announcing anto form a new joint ventureTronoxincreases afterand announcing the closure of its pigment plant in ChinaSareptagains after reporting topline three-yearSatellogicfalls after pricing 7.4M shares at $4.73 inBlackRock TCP Capitallower after5. EARNINGS/GUIDANCESteel Dynamics, with EPS beating consensusBank of Hawaii, with CEO Peter Ho commenting, "Bank of Hawai'i completed 2025 with strong financial performance"Velocity Financialfor Q4 and FY25Trade Deskfor Q4Lakeland Financial, with CEO David Findlay commenting, "The Lake City Bank team produced a very strong fourth quarter with exceptional performance metrics"INDEXES:Near midday, the Dow was up 0.32%, or 155.73, to 49,254.44, the Nasdaq was up 0.67%, or 157.46, to 23,658.71, and the S&P 500 was up 0.56%, or 38.67, to 6,954.28.
IO Biotech Explores Strategic Alternatives to Maximize Shareholder Value
IO Biotech announced that the company intends to explore a range of strategic alternatives to maximize stockholder value. Strategic alternatives that may be evaluated include, but are not limited to, a merger, a business combination, a sale of assets or other strategic transaction or a liquidation and dissolution. The company is also evaluating a further reduction-in-force and other efforts to significantly reduce the company's operating expenses while the company explores a range of strategic alternatives.
IO Biotech Publishes MM1636 Trial Results Showing 25.5-Month Progression-Free Survival
IO Biotech announced the publication in Nature Communications of the long-term clinical and immunological outcomes from MM1636, the Phase 1/2 trial evaluating the investigational peptide vaccine IO102-IO103 targeting both tumor cells and immune-suppressive cells expressing IDO1 and/or PD-L1, in combination with PD-1 blockade in the treatment of first line metastatic melanoma. The results of this trial supported a Breakthrough Therapy Designation for the treatment of unresectable/metastatic melanoma in combination with pembrolizumab by the FDA and, together with the available preclinical and translational data, served as the foundation for IO Biotech's decision to initiate the Phase 3 clinical trial in first-line advanced melanoma. The MM1636 results published showed the five-year follow-up analysis of IO102-IO103 in combination with nivolumab in patients with metastatic melanoma, demonstrating durable clinical activity with a 25.5-month median progression-free survival. The results also showed the identification of potential vaccine-specific immune biomarkers of long-term benefit, not observed in a matched anti-PD-1 monotherapy cohort, suggesting a distinct vaccine-induced immune modulation increasing anti-tumor activity. These overall results provide a compelling rationale for integrating immune-modulatory vaccination into immunotherapy regimens for patients with melanoma.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。









